-- Booth Highlights Include
Persona® OsseoTi® Keel Tibia, a Preview of
ROSA® Shoulder*, Pending 510(k) Clearance, and
the HAMMR™ Automatic Hip Impaction System--
WARSAW,
Ind., Feb. 12, 2024 /PRNewswire/ -- Zimmer
Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical
technology leader, today announced that it is showcasing the latest
innovations across its product portfolio at the 2024 annual meeting
of the American Academy of Orthopaedic Surgeons (AAOS) this week in
San Francisco. During the meeting,
the company will display its forthcoming ROSA® Robotics
application for shoulder replacement,* which is pending
510(k) clearance, and provide hands-on demonstrations of key
growth drivers including
Persona® OsseoTi® Keel Tibia for
cementless knee replacement, ROSA® Robotics (ROSA Knee
and ROSA Hip), Ambulatory Surgery Center (ASC) Solutions, as well
as recently launched surgical tools including HAMMR™ Automatic Hip
Impaction System, and the ViVi® Surgical Helmet
System.
"Every year, the annual AAOS meeting gives us an opportunity to
not only demonstrate the breadth and diversity of our portfolio,
but also shine a spotlight on the bold and meaningful innovations
that transform clinical care, improve the surgical experience, and
give us a differentiated competitive advantage," said Mark Bezjak, President of the Americas at Zimmer
Biomet. "From our cementless construct, Persona OsseoTi Keel Tibia,
to our ROSA Robotics platform powered by ZBEdge™ Dynamic
Intelligence™, we're excited to share our customer-centric
solutions with surgeons from around the world."
Here are the highlights at the Zimmer Biomet booth (#1127):
- Best-in-Class Implants
- Persona® OsseoTi® Keel Tibia for
cementless knee replacement: Launched in 2023, this cementless
construct offers stable*1 initial and biological
fixation with OsseoTi® porous keel design, versatility
to switch between cemented and cementless approach
intra-operatively, and an anatomic design for proper rotation and
optimal bone coverage.
- Surgical Tools
- HAMMR™ Automatic Hip Impaction System for bone
preparation and implant placement during hip replacement surgery:
Designed to deliver consistent and controlled energy2 to
address surgeon strain, fatigue and repetitive motion associated
with a traditional mallet.
- ViVi® Surgical Helmet System that keeps
clinicians cool and comfortable, while providing clear visibility
for precise surgical procedures. Illuminated by a powerful 100,000
Lux LED light, ViVi is the quietest3 and most
lightweight4,5 surgical helmet
available†.
- Robotics and Data Intelligence
- ROSA® Robotics: Comprehensive,
multi-application platform for knee and hip procedures.
Designed for Zimmer Biomet's leading implants and data
technologies, ROSA Robotics redefines robotics by providing
real-time insights with the goal to optimize outcomes and
revolutionize the standard of care.
- ZBEdge™ Dynamic Intelligence™: Elevates and unlocks the
full potential of Zimmer Biomet's cutting-edge digital, robotic and
implant solutions. ZBEdge technologies collect objective data
before, during and after surgery, and then deliver actionable
insights to help surgeons make the most informed decision
possible.
In addition, the company will provide updates on its ASC
strategy, partnerships and comprehensive portfolio. For more
information about Zimmer Biomet events at AAOS 2024, visit
http://www.zimmerbiomet.com/academy2024.
About Zimmer Biomet
Zimmer Biomet is a global medical
technology leader with a comprehensive portfolio designed to
maximize mobility and improve health. We seamlessly transform the
patient experience through our innovative products and suite of
integrated digital and robotic technologies that leverage data,
data analytics and artificial intelligence.
With 90+ years of trusted leadership and proven expertise,
Zimmer Biomet is positioned to deliver the highest quality
solutions to patients and providers. Our legacy continues to come
to life today through our progressive culture of evolution and
innovation.
For more information about our product portfolio, our operations
in 25+ countries and sales in 100+ countries or about joining our
team, visit www.zimmerbiomet.com or follow on LinkedIn at
www.linkedin.com/company/zimmerbiomet or X / Twitter at
www.twitter.com/zimmerbiomet.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains forward-looking
statements within the meaning of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements may be identified by the use of forward-looking terms
such as "may," "will," "expects," "believes," "aims,"
"anticipates," "plans," "looking forward to," "estimates,"
"projects," "assumes," "guides," "targets," "forecasts,"
"continue," "seeks" or the negatives of such terms or other
variations on such terms or comparable terminology. Forward-looking
statements include, but are not limited to, statements concerning
the Company's expectations, plans, intentions, strategies,
prospects, business plans, product and service offerings, new
product launches, potential clinical successes, and other
statements that are not historical facts. Such statements are based
upon the current beliefs and expectations of management and are
subject to significant risks and uncertainties that could cause
actual outcomes and results to differ materially. Some of these
risks and uncertainties can be found in Zimmer Biomet's Annual
Report on Form 10-K for the year ended December 31, 2022 and subsequent periodic reports
filed with the Securities and Exchange Commission (SEC). Copies of
these filings are available online at
www.sec.gov, www.zimmerbiomet.com or
on request from the Company. These factors should not be construed
as exhaustive and should be read in conjunction with the other
cautionary statements that are included in the Company's filings
with the SEC. Such forward-looking statements speak only as of the
date made, and the Company disclaims any intention or obligation to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise. Readers of
this press release are cautioned not to place undue reliance on
these forward-looking statements, since there can be no assurance
that these forward-looking statements will prove to be accurate.
This cautionary statement is applicable to all forward-looking
statements contained in this press release.
References
* ROSA Shoulder is currently pending 510(k) clearance and is not
commercially available.
† Versus market-share leaders
* Laboratory testing may not be indicative of clinical results.
1 Mueller J.K., et al. Persona OsseoTi
Keel Tibia Provides Stable Initial Fixation 4027.2-GLBL-en.
November 2022. Laboratory testing may
not be indicative of clinical results.
2 Data on File at Zimmer Biomet. Zimmer HAMMR
Verification Test Report. DOC0179677. Pages 47-49. January 19, 2024.
3 MD 7.6.3 - TR_ViVi Noise_Competitor Analysis_Rev.01.
Page 2. August 24, 2023. Data on file
at Zimmer Biomet.
4 THI Airflow-Weight-Light-Noise Summary Report ENG.
Page 8. May 31, 2023. Data on file at
Zimmer Biomet.
5 THI - Weight - Noise - FOV file. Page 3. September 26, 2023. Data on file at Zimmer
Biomet.
Media
|
|
Investors
|
Heather
Zoumas-Lubeski
|
|
Zach Weiner
|
445-248-0577
|
|
908-591-6955
|
heather.zoumaslubeski@zimmerbiomet.com
|
|
zach.weiner@zimmerbiomet.com
|
|
|
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/zimmer-biomet-showcases-latest-innovations-across-comprehensive-portfolio-at-aaos-2024-annual-meeting-302059155.html
SOURCE Zimmer Biomet Holdings, Inc.